Wally Sinclair, Ruston Fellows and Leland MacLeod made statements and answered questions.

Cathay Wagantall moved, — That pursuant to Standing Order 108(2), the Standing Committee undertake a study, over 18 meetings, regarding the anti-malaria drug commonly known as Mefloquine, Mefliam, Lariam and other brand names, beginning with the first use of the drug distributed to Canadian Armed Forces (CAF) members through to present day; that this study consider all aspects of the use of mefloquine et al. by the CAF, including but not limited to: distribution, pricing, clinical testing, dosing, follow-up, side effects, a review of the latest research, a comparison with the experience of our allies and other related topics; and that the findings of this study be reported to the House.

Doug Eyolfson moved, — That the debate be now adjourned.

The question was put on the motion and it was agreed to on the following recorded division:

YEAS: Bob Bratina, Shaun Chen, Doug Eyolfson, Peter Fragiskatos, Karen Ludwig — 5;

NAYS: Gord Johns, Robert Kitchen, Phil McColeman, Cathay Wagantall — 4.

Questioning of the witnesses resumed.

At 4:39 p.m., the sitting was suspended.

At 4:47 p.m., the sitting resumed in camera.

It was agreed, — That the motion adopted on Tuesday, February 16, 2016, regarding the Subcommittee on Agenda and Procedure be rescinded and replaced by the following:

That the Subcommittee on Agenda and Procedure be established and be composed of the Chair, the two Vice-Chairs, Bob Bratina and Karen Ludwig.